Remove Allergies Remove Gene Editing Remove RNA
article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. percent in the placebo group.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

2) Veklury (remdesivir) Veklury, approved by the FDA in 2020, is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor designed for the treatment of COVID-19. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. Veklury generated a revenue of $3.91 billion in 2022.

Sales 98
article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.